Solid expects to meet with FDA in late Q4 2026 on SGT-003 accelerated approval pathway
Company expects initial SGT-212 Phase 1b data in Q1 2027, subject to enrollment
Solid anticipates existing cash will fund operations into mid-2028
Result drivers
R&D SPENDING - Higher Q2 research and development expenses mainly due to increased costs for SGT-003 manufacturing and clinical activities, as well as SGT-212 clinical and research costs
G&A EXPENSES - General and administrative expenses rose mainly due to higher personnel, business development, equipment, and consulting costs
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, about 83.3% above its August 5 closing price of $8.73
Q2 results and cash position
US gene therapy developer reported Q2 net loss widened yr/yr on higher R&D and G&A costs
Company ended Q2 with $377.7 mln in cash, expects runway into mid-2028
SLDB•
